Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

NCT07332351 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Urothelial Carcinoma
Stage II Bladder Cancer AJCC v8
Stage IIIA Bladder Cancer AJCC v8

Interventions

BIOLOGICAL: Nadofaragene Firadenovec
BIOLOGICAL: Durvalumab
DRUG: Gemcitabine
DRUG: Cisplatin
PROCEDURE: Radical Cystectomy
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Positron Emission Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

University of Washington

Collaborators

[object Object]